CLEVELAND, June 29 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. , a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported that its unified platform has been selected by a European pharmaceutical company with the objective of standardizing their international clinical trials on this single product suite. This relationship represents another new client for DATATRAK. This selection of DATATRAK eClinical(TM) was made following an extensive evaluation of the world's leading clinical trial technology providers. This client stated that they had evaluated five other competitors in addition to DATATRAK during their global assessment. Products that necessitated integration of disparate technologies were one of the early elimination criteria established by the sponsor's evaluation team. Additionally, during the final phases of the official selection of DATATRAK, the sponsor visited selected sites for their clinical trials that had experience in other ongoing trials with DATATRAK eClinical(TM) and other competing technologies. Ad hoc field tests performed by this sponsor at those sites indicated a consistently faster and more reliable performance of DATATRAK eClinical(TM) compared to others.
This sponsor plans to standardize on DATATRAK eClinical(TM) for not only their clinical trial programs, but also intends on utilizing the same architecture as a company-wide communications portal leveraging the generic workflow capabilities of this technology. The collaboration capabilities of DATATRAK eClinical(TM) can assist in the overall management of documents and tasks necessary to maximize the efficiency of the clinical trial process. The sponsor has signed contracts initially for two clinical trials while instituting plans to stage future clinical trials from their pipeline over to DATATRAK eClinical(TM) throughout the remainder of 2006 and beyond. DATATRAK is working closely with the sponsor on the most efficient processes and workflows that can be used with Contract Research Organizations (CROs) that the sponsor may select to provide additional services in conjunction with DATATRAK eClinical(TM) deployments as part of their clinical trial programs.
DATATRAK eClinical(TM) was chosen because of its unique position in the market of having the broadest and the most unified platform of capabilities existing under one software architecture obviating the need for expensive and risky integration procedures involved with databases residing in unrelated applications. It represents the only clinical trial technology that can collectively house information obtained from electronic case report forms, electrocardiographic- and/or image-generated media associated with increasingly important cardiac safety initiatives and also can facilitate critically important and timely workflow priorities under one interrelated platform.
"The traction and commitment levels from customers that we have experienced over the past few months with our eClinical platform are at all time highs for our Company," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "The ability to unify all clinical trial data is without a doubt the main reason for these commitments. The awarding of new business is excellent, but more importantly, the three customers referred to in the subheading of this announcement have all decided to standardize their clinical programs on DATATRAK and are investigating no other competing technologies at this time. They are content to proceed forward with DATATRAK as their sole provider. This sponsor's plans for the leveraging of technology in their clinical trial process are visionary and will result in their development programs being as efficient as possible in bringing their products to market and in maximally safeguarding patient safety through immediate access and control of information. With an increasing focus towards technology solutions in clinical trials, clinical trial sponsors such as this will definitely have a competitive advantage over companies using legacy methods, point solutions or other technologies that require substantial integration in order to cover all the activities necessary in an efficient global research and development program."
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Technology Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 56 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 15 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at http://www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. Factors that may cause actual results to differ materially from those in the forward- looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market its software; the development and fluctuations in the market for clinical trial technology; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; governmental regulation; the early stage of the Company's business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.
DATATRAK International, Inc.CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief ExecutiveOfficer, ext. 112, or Terry C. Black, Chief Financial Officer, ext. 110,both of DATATRAK International, Inc., +1-440-443-0082; Investor Relations,Neal Feagans, of Feagans Consulting, Inc for DATATRAK International, Inc.,+1-303-449-1184
Web site: http://www.datatrak.net/
